Orthopedic Oncology Market By treatment | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Orthopedic Oncology Market
Orthopedic Oncology Market: By treatment (Surgery, Chemotherapy, Radiation and targeted therapy) & by end user (Hospitals, & Research Labs) & By Geography-Forecast (2016-2021)
Report Code : HCR 0349
Updated Date: 28 January, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
1. Orthopaedic Oncology– Market Overview
2. Executive Summary 
3. Market Landscape
   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Orthopaedic Oncology– Market Forces
   4.1. Drivers
      4.1.1. Rapidly ageing population with increasing risk of developing cancer
   4.2. Restrains
      4.2.1. High cost associated with the treatment for musculoskeletal oncology diseases
   4.3. Opportunities
      4.3.1. Emerging Economies
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Orthopaedic Oncology– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis 
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Orthopaedic Oncology Market, By Treatment
   6.1. Surgery
   6.2. Chemotherapy
   6.3. Radiation
   6.4. targeted therapy
7. Orthopaedic Oncology Market, By End-Use Application
   7.1. Hospitals
   7.2. Research Labs
8. Orthopaedic Oncology Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America 
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Orthopaedic Oncology– Market Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   10.1. Stryker Corporation
   10.2. Accentus Inc.
   10.3. Roche Diagnostics
   10.4. Amgen Inc
   10.5. Novartis AG
   10.6. Biogen Idec
   10.7. GlaxoSmithKline
   10.8. Sanofi S.A
   10.9. Pfizer Inc.
   10.10. Doe & Ingalls Inc.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix
   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of expert Insights
   11.6. Disclaimer
Orthopedic oncology accounts for a small proportion in orthopedics. Orthopedic oncology is a condition that arises due to the formation of benign and malignant tumors in bones and connective soft tissues Globally, Development of efficient and advance technology and rapidly ageing population with increasing risk of developing cancer are the prime growth drivers of global orthopardic oncology market. In addition, emerging economies such as China, India and others, will create new opportunities for global orthopaedic oncology market. However, High cost associated with the treatment for musculoskeletal oncology diseases and lack of awareness regarding the effective treatment therapies are some of the factors which restraint the market growth in the near future 
       
 Orthopedic Oncology Market

Globally market for Orthopediac oncology is expected to be on a higher side in North America and Europe owing to increasing prevalence of cancer and musculoskeletal related disorders. Asia pacific represents immense growth opportunity for orthopedic oncology market attributed to rapidly aging population and rising cancer incidence. In addition macroeconomic factors such as FDA approvals are also expected to increase the adoption rate of devices in the developed countries.

This report identifies the Fine chemicals market size in for the year 2016-2021, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to Orthopaedic Oncology market.


This report on global Orthopaedic Oncology is segmented on the basis of Orthopaedic Oncology application, end-use industries using Orthopaedic Oncology for wide range of end-use applications and market size in various geographical regions.

  • On the basis of treatment of Orthopaedic Oncology, this report is segmented as, Surgery, Chemotherapy, Radiation and targeted therapy] & by end user [Hospitals] and Others
  • This report is also segmented on the basis of end-user such as, hospitals, and research labs
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for Orthopaedic Oncology in each of the region.

This report identifies all the major companies operating in the global Orthopaedic Oncology market. Some of the major companies’ profiles in detail are as follows:
  • Stryker Corporation
  • Accentus Inc
  • Roche Diagnostics
  • Amgen Inc
  • Novartis AG
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll